Tilray Brands, Inc. - Common Stock (TLRY)

The cannabis industry is still finding its footing, but Tilray just posted record revenue with its beverage business turning profitable. Canopy is narrowing losses and targeting positive EBITDA by fiscal year-end.

The company's top line may have increased, but it doesn't take long for investors to spot problems in its recent earnings report.

Canopy pursues a lean U.S.-focused strategy while Tilray has diversified into beverages, but their diverging paths and financial profiles reveal starkly different risk-reward profiles for 2026.

Tilray's stock isn't the bargain it appears to be at first.

Tilray Brands' fiscal Q1 2027 results show beverage revenue up 82% and European medical cannabis growth offsetting weaker Canadian sales, reducing reliance on U.S. federal rescheduling.

BrewDog profitability and record revenue signal diversified growth momentum.

Tilray Brands (NASDAQ:TLRY) reported record first-quarter revenue and gross profit, driven by its BrewDog acquisition, international cannabis growth and pharmaceutical distribution operations, while reaffirming fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million. Net revenue rose 23%

Curaleaf has raised its hostile bid for Aurora Cannabis to $5 per share as Schedule III tax relief fuels cannabis M&A, with Tilray's Oct. 8 earnings seen as a sector barometer.

The stock is down big this year, but that doesn't mean it's overdue for a rally.

Is Tilray's situation hopeless?

The cannabis company is set to report its earnings early next month.

There's a reason why shares keep tumbling, despite signs of a turnaround.

The cannabis stock has been struggling badly this year, but there could be a catalyst up ahead.

The cannabis stock has moved quickly in the past when there's been talk of marijuana reform.

The Tilray bull case is getting stronger without U.S. legalization.

Tilray Brands has moved beyond marijuana, turning itself into a diversified brand manager.

Canopy Growth benefited from growth across all its divisions in the first quarter of fiscal 2027, but does that make it a worthwhile investment?

Don't expect a rebound anytime soon.

The Canadian cannabis companies are both seeing strong growth, but one is a better buy right now.

Recent results and legalization progress aren't the game changers you'd think they'd be for this cannabis stock.

After a huge gold rush, the marijuana sector stumbled, and now consolidation is gaining momentum.

The cannabis stock has struggled despite Tilray achieving solid growth in its most recent fiscal year.

The company's true organic growth is difficult to gauge given its high dependency on acquisitions.

Tilray's distribution segment was the only one that generated double-digit growth in its most recent fiscal year.

Tilray Brands shares jumped 2.23% after hours as quarterly revenue beat estimates, despite earnings per share missing expectations.